Search results for "Pyrimidine"

showing 10 items of 589 documents

CCDC 1018429: Experimental Crystal Structure Determination

2015

Related Article: José Martínez-Lillo , Donatella Armentano , Francisco R. Fortea-Pérez , Salah-Eddine Stiriba , Giovanni De Munno , Francesc Lloret , Miguel Julve , and Juan Faus|2015|Inorg.Chem.|54|4594|doi:10.1021/acs.inorgchem.5b00502

Space GroupCrystallographycatena-[(mu-22'-bipyrimidine)-(mu-pyrazine)-(mu-chloro)-octachloro-copper-di-rhenium nitromethane monohydrate]Crystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 235075: Experimental Crystal Structure Determination

2005

Related Article: J.Pasan, J.Sanchiz, C.Ruiz-Perez, F.Lloret, M.Julve|2004|Eur.J.Inorg.Chem.||4081|doi:10.1002/ejic.200400260

Space GroupCrystallographycatena-[(mu~2~-Phenylmalonato)-(22'-bipyrimidine)-copper(ii)]Crystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 2018386: Experimental Crystal Structure Determination

2020

Related Article: Rubén Turo-Cortés, Carlos Bartual-Murgui, Javier Castells-Gil, M. Carmen Muñoz, Carlos Martí-Gastaldo, José Antonio Real|2020|Chemical Science|11|11224|doi:10.1039/D0SC04246C

Space GroupCrystallographycatena-[octakis(mu-cyano)-tetrakis(5-aminopyrimidine)-di-iron(ii)-di-platinum(ii) ethanol solvate]Crystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 2018387: Experimental Crystal Structure Determination

2020

Related Article: Rubén Turo-Cortés, Carlos Bartual-Murgui, Javier Castells-Gil, M. Carmen Muñoz, Carlos Martí-Gastaldo, José Antonio Real|2020|Chemical Science|11|11224|doi:10.1039/D0SC04246C

Space GroupCrystallographycatena-[octakis(mu-cyano)-tetrakis(5-aminopyrimidine)-di-iron(ii)-di-platinum(ii) ethanol solvate]Crystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 826153: Experimental Crystal Structure Determination

2013

Related Article: A.R.Stefankiewicz, G.Rogez, J.Harrowfield, A.N.Sobolev, A.Madalan, J.Huuskonen, K.Rissanen, J.-M.Lehn|2012|Dalton Trans.|41|13848|doi:10.1039/c2dt31384g

Space GroupCrystallographytetrakis(mu~2~-46-Bis(2-(1H-imidazol-4-ylmethylene)-1-methylhydrazino)-2-phenylpyrimidine)-tetra-zinc octakis(pperchlorate) acetonitrile solvate tetrahydrateCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 764599: Experimental Crystal Structure Determination

2010

Related Article: D.Visinescu, O.Fabelo, C.Ruiz-Perez, F.Lloret, M.Julve|2010|CrystEngComm|12|2454|doi:10.1039/c002305a

Space GroupCrystallographytetrakis(mu~2~-Cyano)-(mu~2~-22'-bipyrimidine)-hexa-aqua-dodecacyano-bis(nitrato-OO')-tetrakis(110-phenanthroline-NN')-di-dysprosium(iii)-tetra-iron(iii) octahydrateCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 764597: Experimental Crystal Structure Determination

2010

Related Article: D.Visinescu, O.Fabelo, C.Ruiz-Perez, F.Lloret, M.Julve|2010|CrystEngComm|12|2454|doi:10.1039/c002305a

Space GroupCrystallographytetrakis(mu~2~-Cyano)-(mu~2~-22'-bipyrimidine)-hexa-aqua-dodecacyano-bis(nitrato-OO')-tetrakis(110-phenanthroline-NN')-di-europium(iii)-tetra-iron(iii) octahydrateCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 764600: Experimental Crystal Structure Determination

2010

Related Article: D.Visinescu, O.Fabelo, C.Ruiz-Perez, F.Lloret, M.Julve|2010|CrystEngComm|12|2454|doi:10.1039/c002305a

Space GroupCrystallographytetrakis(mu~2~-Cyano)-(mu~2~-22'-bipyrimidine)-hexa-aqua-dodecacyano-bis(nitrato-OO')-tetrakis(110-phenanthroline-NN')-di-holmium(iii)-tetra-iron(iii) octahydrateCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 2081829: Experimental Crystal Structure Determination

2021

Related Article: Alexandros A. Kitos, Diogo A. Gálico, Niki Mavragani, Raúl Castañeda, Jani O. Moilanen, Jaclyn L. Brusso, Muralee Murugesu|2021|Chem.Commun.|57|7818|doi:10.1039/D1CC02407H

Space GroupCrystallographytris(acetylacetonato)-(pyrimidine-2-carboximidamide)-dysprosiumCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

Stochastic dynamics of leukemic cells under an intermittent targeted therapy

2009

The evolutionary dynamics of cancerous cell populations in a model of Chronic Myeloid Leukemia (CML) is investigated in the presence of an intermittent targeted therapy. Cancer development and progression is modeled by simulating the stochastic evolution of initially healthy cells which can experience genetic mutations and modify their reproductive behavior, becoming leukemic clones. Front line therapy for the treatment of patients affected by CML is based on the administration of tyrosine kinase inhibitors, namely imatinib (Gleevec) or, more recently, dasatinib or nilotinib. Despite the fact that they represent the first example of a successful molecular targeted therapy, the development o…

Statistics and ProbabilityComplex systemsmedicine.medical_treatmentModels BiologicalPiperazinesSettore FIS/03 - Fisica Della MateriaCancer evolutionTargeted therapyLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesStochastic dynamics; Cancer evolution; Complex systemsHumansMedicineComputer SimulationStochastic dynamicMolecular Targeted TherapyProtein Kinase InhibitorsEcology Evolution Behavior and SystematicsStochastic Processesbusiness.industryApplied MathematicsMyeloid leukemiaImatinibmedicine.diseaseSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)DasatinibLeukemiaPyrimidinesImatinib mesylateNilotinibStochastic dynamics Monte Carlo simulationBenzamidesImmunologyCancer cellDisease ProgressionImatinib MesylateCancer researchbusinessmedicine.drug
researchProduct